



ASX Announcement

For immediate release

17 August 2021

Appointment of New Non-Executive Director

CSL Limited (ASX:CSL; USOTC:CSLLY) today announces the appointment of Professor Duncan Maskell as an independent Non-executive Director, to be effective from 18 August 2021.

CSL's Chair, Dr Brian McNamee AO said "Professor Maskell is an exceptional addition to the CSL Board. He brings wide-ranging international experience in science and commerce, developed across a rich 30-year career in research, academia and entrepreneurship. These areas represent the core of what we do at CSL and his contribution will strengthen the Board's range of experience."

Professor Maskell is the Vice-Chancellor of the University of Melbourne. Prior to this he was Senior Pro-Vice-Chancellor at the University of Cambridge in the United Kingdom, where he was responsible for planning and resources for the institution's operations with an annual turnover of approximately GBP2 billion.

A research specialist in infectious diseases, Professor Maskell has also held roles at the University of Oxford, Imperial College London and Wellcome Biotech.

Professor Maskell has had extensive experience across the private sector, reflecting his passion for the commercialisation of research initiatives. He has co-founded several biotech companies, including Arrow Therapeutics, which was sold to biopharmaceutical company AstraZeneca, and Discuva, which was sold to Summit Therapeutics. He has also served as a Non-executive Director of Genus Plc, a FTSE 250 company.

Professor Maskell holds a Master of Arts and a Doctor of Philosophy from the University of Cambridge.

Authorised by
Fiona Mead
Company Secretary



ASX Announcement

Page 2

FURTHER INFORMATION

For further information, please contact:

Investors:

Mark Dehring
Head of Investor Relations
CSL Limited
Telephone: +613 9389 3407
Email: mark.dehring@csl.com.au

Media:

Jimmy Baker
Communications, Asia Pacific
CSL Limited
Mobile +61 450 909 211
Email: jimmy.baker@csl.com.au

© Trademarks of CSL Limited or its affiliates.